RESUMEN

Pyridoxine-unresponsive homocystinuria has lifelong implications for health. In this issue, Perreault and colleagues present evidence that orally delivered engineered probiotic Escherichia Coli Nissle SYNB1353 is a promising candidate in reducing homocysteine, with successful trials in mice, monkeys, and humans. However, further probiotic optimization and safety assessments are required.

Asunto(s)

Homocistinuria , Probióticos , Ratones , Humanos , Animales , Homocistinuria/genética , Homocistinuria/terapia , Escherichia coli/genética , Probióticos/uso terapéutico , Piridoxina , Homocisteína